首页> 美国卫生研究院文献>Springer Open Choice >Phase 1 study of ganitumab (AMG 479) a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R) in Japanese patients with advanced solid tumors

【2h】

Phase 1 study of ganitumab (AMG 479) a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R) in Japanese patients with advanced solid tumors

机译：ganitumab（AMG 479）的1期研究在日本患有晚期实体瘤的患者中它是针对人胰岛素样生长因子I型（IGF1R）的完全人类单克隆抗体

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

PurposeThis study was to investigate the safety and tolerability of ganitumab in Japanese patients with advanced solid tumors.

机译：目的本研究旨在研究加尼他单抗在日本晚期实体瘤患者中的安全性和耐受性。

著录项

期刊名称 Springer Open Choice
作者
Haruyasu Murakami; Toshihiko Doi; Nobuyuki Yamamoto; Junichiro Watanabe; Narikazu Boku; Nozomu Fuse; Takayuki Yoshino; Atsushi Ohtsu; Satoru Otani; Kazuhiro Shibayama; Takatoshi Takubo; Elwyn Loh;
展开▼
作者单位

展开▼
年(卷),期 -1(70),3
年度 -1
页码 407–414
总页数 8
原文格式 PDF
正文语种
中图分类外科学 ;
关键词
Clinical trial phase 1; Ganitumab; Gemcitabine; Insulin-like growth factor receptor type 1;

机译：临床试验;第一阶段;加尼单抗;吉西他滨;胰岛素样生长因子受体1型;

相似文献

外文文献
中文文献
专利

1. Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type i (IGF1R), in Japanese patients with advanced solid tumors [J] . MurakamiH., DoiT., YamamotoN., Cancer chemotherapy and pharmacology. . 2012 ,第3期

机译：ganitumab（AMG 479）的1期研究在日本患有晚期实体瘤的患者中，它是一种针对人胰岛素样生长因子I型（IGF1R）的完全人类单克隆抗体
2. Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors [J] . Haruyasu Murakami, Toshihiko Doi, Nobuyuki Yamamoto, Cancer Chemotherapy and Pharmacology . 2012 ,第3期

机译：ganitumab（AMG 479）的1期研究在日本患有晚期实体瘤的患者中，它是针对人胰岛素样生长因子I型（IGF1R）的完全人类单克隆抗体
3. Safety, tolerability, pharmacokinetics and antitumor activity of ganitumab, an investigational fully human monoclonal antibody to insulin-like growth factor type 1 receptor, combined with gemcitabine as first-line therapy in patients with metastatic pancreatic cancer: a phase 1b study. [J] . OkusakaT., IkedaM., FukutomiA., Japanese journal of clinical oncology. . 2014 ,第5期

机译：Ganitumab的安全性，耐受性，药代动力学和抗肿瘤活性，一种针对胰岛素样生长因子1型受体的研究性全人类单克隆抗体，结合吉西他滨作为转移性胰腺癌患者的一线治疗药物：1b期研究。
4. HER1 THERAPEUTIC CANCER VACCINE: AN ACTIVE IMMUNOTHERAPY TREATMENT FOR PATIENTS WITH TUMORS EXPRESSING THE RECEPTOR OF EPIDERMAL GROWTH FACTOR (EGF-R) [C] . Eduardo Suarez, Belinda Sanchez, Zaima Mazorra, Conference on vaccine technology VI . 2018

机译：HER1癌症治疗疫苗：一种针对表皮生长因子（EGF-R）受体的肿瘤的主动免疫疗法
5. The role of the type I insulin-like growth factor receptor in lung tumorigenesis [D] . Siwicky, Megan Danielle. 2009

机译：I型胰岛素样生长因子受体在肺肿瘤发生中的作用
6. Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R) administered in combination with anticancer therapies to patients with advanced solid tumors [O] . V. M. Macaulay, M. R. Middleton, A. S. Protheroe, -1

机译：针对1型胰岛素样生长因子受体（IGF-1R）的人源化单克隆抗体AVE1642的I期研究与抗癌药物联合用于晚期实体瘤患者
7. Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors [O] . Haruyasu Murakami, Toshihiko Doi, Nobuyuki Yamamoto, 2012

机译：ganitumab（AMG 479）的1期研究在日本患有晚期实体瘤的患者中，它是针对I型胰岛素样生长因子受体（IGF1R）的完全人类单克隆抗体
8. Type-I Insulin-Like Growth Factor Receptor (IGF1R)-Estrogen Receptor (ER) Crosstalk Contributes to Antiestrogen Therapy Resistance in Breast Cancer Cells. [R] . Fagan, D. 2013

机译：I型胰岛素样生长因子受体（IGF1R） - 雌激素受体（ER）串扰有助于乳腺癌细胞中的抗雌激素治疗抗性。

Phase 1 study of ganitumab (AMG 479) a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R) in Japanese patients with advanced solid tumors

摘要

著录项

相似文献

相关主题

期刊订阅